PARIS--(BUSINESS WIRE)--HRA Pharma today announced the start of a pivotal multi-centre Phase III study evaluating its proprietary second-generation emergency contraceptive – Ella®. The study will be conducted in sixteen clinics affiliated with Planned Parenthood Federation of America (PPFA) in seven different US states.
